An innovative drug delivery platform for the benefit of patients and pharma company

LIDDS AB (publ) develops injectable drugs for cancer and other diseases based on our unique proprietary NanoZolid® technology. NanoZolid® helps solve some of the main problems with the way drugs work in the body and which affect patient quality of life. NanoZolid® enables the controlled, long-term and personalized release of drugs for up to six months. NanoZolid® can be combined with traditional small molecules as well as with larger molecules.

LIDDS has a broad range of projects where NanoZolid® is combined with cytotoxic drugs used in the treatment of cancer as well as projects in the fast-growing area of immuno-oncology. LIDDS most advanced project is Liproca® Depot, a product for local treatment of prostate cancer.

LIDDS also offers the pharmaceutical industry access to NanoZolid for their drug development projects through licensing agreements. LIDDS recently concluded a licensing agreement in China and has a number of other agreements in place. The development of these projects is subject to the research and business priorities of the licensees.

Industrial scale manufacturing is undertaken in collaboration with Recipharm. LIDDS has other development projects where NanoZolid® is combined with pharmaceutical substances, for example cytostatics and immunological drugs.

LIDDS was founded by scientists and entrepreneurs at Uppsala University, University of Gothenburg and the life science incubator PULS AB. LIDDS shares are traded on Nasdaq Stockholm First North.

Improving quality of life for patients

A key challenge in all drug development is to balance effect and safety. An effective treatment will always bring a certain risk of side-effects. Not only does this cause the patient discomfort, but in order to keep the side-effects at a manageable level it may be necessary to limit the dose of the drug to a level where it may not be as effective as desired. NanoZolid® offers a solution to this dilemma with the controlled and personalized release of active drugs, resulting in fewer side effects and less frequent injections.

Systemic treatment of severe diseases such as cancer means that very potent substances will affect several organs, not just the site of the tumor. Large parts of the body are exposed to the effects and side effects of the drug. This limits the dose and adversely affects the patient’s quality of life. LIDDS NanoZolid® technology allows the local treatment of cancer and other diseases without the serious side effects that occur with systemic treatments.

NanoZolid® controlled drug release can also be used for the treatment of systemic diseases where it is administered subcutaneously resulting in fewer treatments, increased patient compliance and reduced healthcare costs.



The NanoZolid® platform is unique and constantly creates new business opportunities.

Exciting autumn ahead!

We have an exciting autumn ahead of us, not least because of the forthcoming results from our most advanced project – the prostate cancer drug Liproca® Depot (LPC-004). As early as September we are planning to communicate the preliminary results.

It is also very pleasing that the Phase IIb study’s results will be presented as ‘Late Breaking News’ at EUMC (Multidisciplinary Congress on Urological Cancers) in Vienna by Laurence Klotz, a Professor at the Sunnybrook Hospital in Toronto. Professor Klotz is a world-leading expert in prostate cancer and Active Surveillance and one of the participating urologists in the LPC-004 study.

The Phase IIb study includes a total of 61 patients. A number of these patients have chosen to participate in an Open Label Extension (OLE) study in which they will be treated with a further Liproca® Depot injection. The injection is administered when the patient’s PSA level has returned to its original level, i.e. their PSA level prior to the first Liproca® Depot treatment. Preliminary results from several patients in the OLE study look promising and indicate that the anti-androgen effect of Liproca® Depot appears to be significantly longer than six months, which would mean longer treatment intervals and fewer treatments.

LIDDS other clinical project (NZ-DTX) is in Phase I and targets the treatment of solid tumors with NanoZolid® in combination with docetaxel, a cytostatic which is used against many different types of cancer. The first patient has been treated without complications at the Karolinska University Hospital and we look forward to more patients being recruited there and to new clinics joining the study.

Extensive work is underway to prepare for and conclude licensing agreements for Liproca® Depot. Under the existing licensing agreement for Liproca® Depot in China, our partner Jiangxi Puheng is planning to apply to the Chinese drug regulatory agency once the LPC-004 results have been released. Forthcoming clinical studies in China will be fully funded by Jiangxi Puheng.

In addition to the clinical projects, LIDDS has several projects in development with different types of immuno-active drugs. Immuno-therapy is a very promising treatment approach in cancer care. Many large pharmaceutical companies are making significant investments in pre-clinical and clinical research. We view our technology – which provides the opportunity for intratumoral treatment – as being able to improve treatment as immuno-therapies can often result in serious side-effects when certain immuno-active drugs are administered systemically, that is directly into the bloodstream.

Positive pre-clinical studies have been carried by LIDDS with a TLR9 agonist and a comprehensive pre-clinical program is underway. We have recently received confirmation that LIDDS can develop its own product with this specific TLR9 agonist, a positive ‘Freedom-to-Operate’ analysis. We are therefore planning to carry out a Phase I study which is expected to start next year. Based on positive results, LIDDS will be able license out its own product for intratumoral treatment with patent protection until 2037.

NanoZolid® in combination with a STING agonist is another immuno-therapy project under development where there will be the opportunity to out license as soon as the pre-clinical program is complete.

In parallel LIDDS is evaluating additional immuno-activating substances which meet the company’s criteria of being unique and with strong potential for commercialization.

Based on the NanoZolid® technology platform, LIDDS will develop innovative and effective treatments through intratumoral administration while avoiding troublesome systemic impacts. Our vision and goal is that NanoZolid®-based drugs will be at least as effective as the original drug but with fewer side effects and require fewer treatment sessions for patients. In this way our drugs will create value for patients, healthcare providers and the pharmaceutical industry.



Monica Wallter


LIDDS enables new treatments and revitalizes existing products

LIDDS business strategy is to use the NanoZolid® technology for three purposes: In our own in-house drug development, for out- licensing to other pharmaceutical companies for use in their drug development projects, and as a tool for life cycle management of established medicines. LIDDS business model means that development lead times for NanoZolid® are significantly shorter than for traditional pharmaceutical companies.

In-house drug development

LIDDS objective is to develop pharmaceutical products in combination with NanoZolid® that are as effective as the original compounds but with fewer side effects. We aim to out-license our projects to pharmaceutical companies after the pre-clinical phases or phase I or II, subject to indications. Our most advanced project, Liproca® Depot for the treatment of prostate cancer, is currently in a Phase IIb clinical trial. LIDDS has concluded a licensing and development agreement in China for Liproca® Depot.

LIDDS has ongoing preclinical projects for cytotoxic drugs and local immunotherapy. There are also a number of other areas where the unique NanoZolid® technology can bring great benefits, including inflammatory diseases and other areas where patient compliance and convenience are drivers.

Collaborative drug development

LIDDS offers pharmaceutical companies access to NanoZolid® for their drug development projects through licensing agreements. Under these licensing agreements, LIDDS provides the NanoZolid®-based formulation for further development by our partner. The continued development of these projects is subject to the research and business priorities of the licensees.

Rejuvenating established products

With NanoZolid®, LIDDS also offers a patented solution that addresses life cycle management in the pharmaceutical industry. NanoZolid® can be used to reformulate drugs that require improvement or prolonged patent protection.

LIDDS enables new treatments and revitalizes existing products

LIDDS develops new and unique solutions to address common problems related to drugs, in particular the devastating side effects and frequent treatments that are required with pills or injections.

The NanoZolid® technology has been validated with clinical results in Phase II studies and can be used in combination with many different types of pharmaceutical molecules. As a result, our research pipeline in is broad, targeting several cancer and tumor types using both new and well-established drugs, as well as the treatment of systemic diseases where convenience and patient compliance are drivers.

LIDDS plans to out-license projects to pharmaceutical companies after the pre-clinical phases or phase I or II, subject to indications. The Liproca® Depot prostate cancer project is planned to be out-licensed after phase II whereas other projects such as solid tumor treatment with cytotoxic drugs is typically a phase I opportunity.

Following the successful pre-clinical study in immuno-oncology using a STING-agonist, LIDDS is looking to out-license NanoZolid® for this purpose as early as possible, subject to research results.

LIDDS expects a license agreement to include upfront payment, milestone payments and royalty.

Partnering with Recipharm, the GMP manufacturing process is validated in industrial scale for our prostate cancer product, Liproca® Depot.

Board directors and auditors

Jan Törnell
Chairman of the Board since 2015

Born 1960. 15 years of experience in executive roles in the pharmaceutical industry in various countries. Professor with medical background. CEO of Oncorena AB and AB Innoext. Former Vice President of Global Strategy for AstraZeneca Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy, University of Gothenburg. Chairman of Glactone Pharma AB and board member of Diaprost AB. Partners in P.U.L.S. and member of the investment committee.

Independent in relation to LIDDS AB (publ), its management and the principal shareholders.

Holdings: 42 909 shares

Daniel Lifveredson
Board member since 2017

Born 1976. Master of Science in Engineering, Industrial Economy, Chalmers tekniska högskola in Gothenburg. CEO and owner of Excore AB, specialized in counseling in connection with corporate transactions in the segment of medium-sized companies. Long experience in international business. Daniel Lifveredson is engaged as a partner in several companies.

Independent in relation to LIDDS AB (publ), its management and the principal shareholders.

Holdings: 2 190 675 shares

qIngaLill Forslund Larsson
Board member since 2015

Born 1954. Economist with specialization in Marketing from the University of Uppsala. Leg. Midwife. Many years of sales and marketing responsibility in the pharmaceutical industry, including business responsibility for Urology, Global Marketing at Ferring Pharmaceuticals. Has held several commercial roles at AstraZeneca, among other things, responsible for a number of product launches. Senior Consultant at Lisberg Executive Search and Boyden International. CEO of a private real estate and consulting company. Board experience from several life science companies.

Independent in relation to LIDDS AB (publ), its management and the principal shareholders.

Holdings: 11 249 shares, 0 warrants

Maria Forss
Board member since 2015

Born 1972. Master’s degree in Economics from the School of Business, Economics and Law and Concordia University, Montreal. Active at the Swedish listed company Vitrolife since 2012, currently in the role as Vice President Consumables and Site Manager for two operation sites. Maria Forss has for more than 20 years worked with product development, business development,  marketing of pharmaceutical products in global roles at AstraZeneca, as well as in the virtual company DuoCort, where she as CEO and project managers had been instructed to take a new drug from clinical trials to regulatory approval and sales of the company. She has experience in product development of medicines from early phase to commercialization, and from several board positions in the pharmaceutical and medical technology companies.

Independent in relation to LIDDS AB (publ), its management and the principal shareholders.

Holdings: 22 893 shares, 0 warrants

Anders Bjartell
Board member since 2015

Born 1959. Professor and chief of urology at Skåne University Hospital since 2006. PhD in Medical cell research. European specialist degree in Urology. Visiting investigator at Memorial Sloan-Kettering Cancer Center in New York, 2005-2007. Associate Editor of European Urology, 2005-2012. Responsible for clinical trials in prostate cancer at the urology clinic SUS Malmö since 2007. National Principal Investigator for several new drugs for prostate cancer in recent years. Research group leader for urological cancer research at the Institute for Translational Medicine at Lund University. Published over 200 original scientific articles. H-index 39. Have experience in board work in European Urology, foundations and life science.

Independent in relation to LIDDS AB (publ), its management and the principal shareholders.

Holdings: 13 724 shares, 0 warrants

David Bejker
Board member since 2019

Born 1975. MSc from the Stockholm School of Economics. David Bejker is the CEO of listed company Affibody Medical AB, a company that develops innovative protein drugs, since 2008. David Bejker has extensive industry experience both from an investor’s point of view, through employment within HealthCap, and operating as a business developer of Affibody AB in the years 2003 to 2005. David Bejker has been CEO of Affibody during a period when the company successfully became a financially strong biotechnology pharmaceutical company with projects in clinical development as well as a large number of global licensing and collaboration business. Affibody has under his leadership also secured large research grants from EU, NCI and Vinnova.

Independent in relation to LIDDS AB (publ), its management and the principal shareholders.

Holdings: 5 624 shares, 0 warrants

Öhrlings PricewaterhouseCoopers AB

Visiting address: Klostergatan 9

Box 179

751 04 Uppsala

Telephone: 010 – 212 61 60

Senior executives and management

Monica Wallter

International Diploma in Marketing & Economics from University of Lund, Sweden.
Former CEO of Ellen AB (publ) from 2008 to 2014 and CEO of Probi AB (publ) 2000-2003. Senior international management positions in Pharmacia between 1986-1995. Global Category Director at Pharmacia & Upjohn during 1996-2000. Monica has worked at LIDDS since 2015.

Holdings: 22 521 shares, 0 warrants

Anja Peters Ohlsson
CFO and Head of IR

Master degree in Business and Economics, University of Uppsala, Sweden. Former CFO of Allenex AB (publ) and CareDx AB. CFO and Head of IR at Kontigo Care AB (publ). Anja has also worked as an authorized accountant at EY for 16 years. Born 1970. Anja has worked at LIDDS since 2019.

Holdings: 0 shares, 0 warrants

Stefan Grudén
Director of pharmaceutical R & D

Pharmacists, M.Sc. Pharm., From Uppsala University. 17 years experience in pharmaceutical research and development, including 15 years in senior services and Pharmacy Manager both Galenica AB, Malmö and Orexo AB, Uppsala, Sweden. Participated in the development of over 50 projects, of which more than a third have been upscaled to production scale and currently on the market as commercial products. Have a vast experience in solid and semi-solid drug delivery technologies. He comes from a position as Innovation Coordinator of Orexo AB. Born 1972. Stefan has worked at LIDDS since 2014.

Holdings: 562 shares, 0 warrants

Niklas Axén
Director of Biomaterials & Devices

M.Sc. Engineering Physics at Uppsala University, PhD and Associate Professor of Materials Science at Uppsala University. Niklas Axen has previously worked in product development at De Beers and Hemapure, and has been in charge of R & D including Cerbio AB, Doxa AB and AB OrtoWay. Born 1963. Niklas has worked at LIDDS since 2003.

Holdings: 56 249 shares, 0 warrants

Martin Johansson
Head of preclinical R&D in immunotherapy

M.Sc. chemical engineering Lund University, Ph.D. and associate professor in organic chemistry at Lund University. 17 years of experience in medicinal chemistry and preclinical research and development. Formed Chief Scientific Officer with Respiratorius AB and senior research scientist at AstraZeneca Discovery R&D Södertälje Discovery R&D, Södertälje. Project manager for Glactone Pharma AB. Born 1971. Martin has worked at LIDDS since 2016.

Holdings: 562 shares, 0 warrants

Charlotta Gauffin
Head of Clinical Trial Management

Master of Science M.Sc. and Ph.D. in organic chemistry from Uppsala University. About 20 years of experience in the pharmaceutical industry, within research and clinical development. Has held senior clinical project management positions at Quintiles and Q-Med/Galderma, with experience from a range of indications within drug and medical devicedevelopment. Born 1971. Charlotta has worked at LIDDS since 2019.

Holdings: 0 shares, 0 warrants

Erwin Brenndörfer
Head of Translational Medicine

M.Sc. in biochemistry from Tübingen University, Ph.D. from Düsseldorf University. 15 years of experience in both immunology and oncology research and development from the pharmaceutical industry and academia. Has held positions as project leader at Medivir and the Karolinska Institute and has an extensive experience in preclinical drug development, in vivo pharmacology, and project management. Born 1977. Erwin has worked at LIDDS since 2019.

Holdings: 0 shares, 0 warrants